Neuroinflammation and neurohormesis in the pathogenesis of Alzheimer’s disease and Alzheimer-linked pathologies: modulation by nutritional mushrooms
- 1.3k Downloads
Human life develops and expands not only in time and space, but also in the retrograde permanent recollection and interweaving of memories. Therefore, individual human identity depends fully on a proper access to the autobiographical memory. Such access is hindered or lost under pathological conditions such as Alzheimer’s disease, including recently associated oxidant pathologies, such as ocular neural degeneration occurring in glaucoma or neurosensorial degeneration occurring in Menière’s disease. Oxidative stress and altered antioxidant systems have been suggested to play a role in the aetiology of major neurodegenerative disorders, and altered expression of genes sensing oxidative stress, as well as decreased cellular stress response mechanisms could synergistically contribute to the course of these oxidant disorders. Thus, the theory that low levels of stress can produce protective responses against the pathogenic processes is a frontier area of neurobiological research focal to understanding and developing therapeutic approaches to neurodegenerative disorders. Herein, we discuss cellular mechanisms underlying AD neuroinflammatory pathogenesis that are contributory to Alzheimer’s disease. We describe endogenous cellular defence mechanism modulation and neurohormesis as a potentially innovative approach to therapeutics for AD and other neurodegenerative conditions that are associated with mitochondrial dysfunction and neuroinflammation. Particularly, we consider the emerging role of the inflammasome as an important component of the neuroprotective network, as well as the importance of Coriolus and Hericium nutritional mushrooms in redox stress responsive mechanisms and neuroprotection.
KeywordsOxidative stress Neurodegenerative disorders Neurohormesis Mushrooms
Absent in melanoma 2
Lipoxin A4 receptor
Apoptotic speck-containing protein
Aspirin triggered lipoxin A4
Cerebral blood flow
Damage associated molecular pattern
Electron transport chain
N-formyl-peptide receptor 1
G protein-coupled receptors
Heme oxygenase 1
Heat shock protein 70
Heat shock protein 72
Heat shock proteins
Nuclear factor kappa B
Nerve growth factor
PYD domains-containing protein 3
Polysaccharide K or Krestin
Retinal ganglion cell
Radical oxygen species
Alzheimer’s disease (AD) is a neurodegenerative progressive disorder affecting more than 15 million people worldwide and represents the most current cause of dementia in the elderly, accounting for 50–60% of all cases in Western world .
The pathological signs of AD are amyloid plaques containing amyloid-β (Aβ) peptide derived from trans-amyloid precursor protein and neurofibrillary tangles constituted by hyper phosphorylated tau protein in medial temporal lobe structures and cortical areas of the brain along with neuronal death and synapse loss . It has been demonstrated that inflammation cascade is linked to neurodegenerative diseases, particularly, Alzheimer’s disease (AD) [3, 4]. In order to resist to different injuries, brain cells have developed networks of responses that detect and control different forms of stress [5, 6]. These are mainly proteins, including heat shock proteins (Hsps), lipoxin A4 (LXA4), thioredoxin (Trx) and sirtuins, controlled by vitagenes, a redox-dependent complex of genes . LXA4 is an endogenous eicosanoid, produced by arachidonic acid metabolism, endowed with anti-inflammatory properties in different inflammatory syndromes, such as periodontitis, nephritis, arthritis, inflammatory bowel disease. LXA4 blocks the productions of pro-inflammatory mediators including free radical oxygen and nitrogen reactive intermediates (ROS/RNS), and acts as an endogenous “braking signal” in the inflammatory process. It is generally acknowledged as “signal stop” of inflammation . The discovery of agents capable of increasing LXA4 levels and subsequently Aβ uptake by phagocytic cells is increasingly being recognized as a potential therapeutic target for AD treatment. Previous studies have demonstrated that mushrooms significantly up-regulate LXA4 in the brain. Mushrooms have been used in traditional medicine, for many years , and a long list of therapeutic properties exists that have been associated with mushroom extracts, including antitumor, immunomodulatory, antioxidant, antiviral, antibacterial, and hepatoprotective effects. Mushrooms are a rich font of polysaccharides, and many of them have been shown to stimulate host immune responses. Among the most powerful known immunostimulators, β-glucans derived from mushrooms stimulate immune cells and cytokine responses [8, 10].
Taken into account the fact that Alzheimer’s disease is characterized by neurodegeneration associated with neuroinflammation, in our recent study we have shown that Coriolus versicolor and Hericium erinaceus biomass preparations have neuroprotective effects and act by modulating the inflammatory process associated with the pathology of AD, as well as regulating brain cellular stress response mechanisms .
There is a growing body of evidence demonstrating a link between Alzheimer’s disease and glaucoma. Notably, amyloid deposits, constituted of amyloid beta (Αβ) aggregates, a characteristic feature of several neurodegenerative diseases, such as Alzheimer’s, mild cognitive impairment and Parkinson’s disease (PD), have been recently implicated in the pathogenesis of retinal damage, of age-related macular degeneration and glaucoma. Glaucoma is a progressive optic neuropathy characterized by gradual degeneration of neuronal tissue due to retinal ganglion cell loss, associated to visual field loss over time resulting in irreversible blindness [11, 12]. It is a leading cause of irreversible blindness estimated to affect 79.6 million people worldwide by 2020. Accumulation of Aβ characterizes glaucoma as a protein misfolding disease, suggesting a pathogenic role for oxidative stress in the pathogenesis of retinal degenerative damage associated to this ocular pathology. In particular, factors such as tissue hypoxia and disturbed protein metabolism have been identified to interact in a vicious cycle underlying the oxidative stress-driven pathogenesis of glaucoma, ultimately leading to apoptotic retina ganglion cell death . Research studies have demonstrated that retinal ganglion cell (RGC) damage in glaucoma is not limited to the primary insulted neurons, but also involves neighbouring neurons. In view of these considerations glaucoma can be viewed as a neurodegenerative disease which, similarly to other neurodegenerative pathologies, i.e., Alzheimer’s and Parkinson’s disease, where irreversible functional deficit ensues as consequence of neuronal dysfunction and death. Interestingly, recent evidence from our laboratory have demonstrated higher levels of vitagenes Heat Shock Protein 72 (Hsp72) and Heme oxygenase (HO-1) in the blood of patients with glaucoma than in controls . These changes were associated with an increased expression of Trx and sirtuin 1 in the same experimental group. Similar results have been found in another oxidant disorder impacted by a progressive degenerative damage of neurosensorial acustic system, such as Ménière’s disease . Ménière’s disease (MD) is characterized by the triad of fluctuating hearing loss, episodic vertigo and tinnitus, and by endolymphatic hydrops found on post-mortem examination. Increasing evidence suggests that oxidative stress is involved in the development of endolymphatic hydrops and that cellular damage and apoptotic cell death might contribute to the sensorineural hearing loss found in later stages of MD . Consistent with this notion, studies are presently under way in our laboratory testing the conceivable possibility that mushrooms supplementation can reverse oxidative damage, thereby affecting the clinical course of Meniere’s disease pathology. Thus, modulation of endogenous cellular defense mechanisms such as the vitagene network may open to new therapeutic approaches in diseases associated with tissue damage and cell death, such as in glaucomatous or Meniere neurodegeneration [14, 15]. In this review, we specifically discuss the main neuroprotective and nutritional activities of Coriolus and Hericium mushrooms. Moreover, we will introduce the emerging role of hormesis and inflammasome as important components of neuroprotective network operating in redox-dependent brain cell stress responsive mechanisms. Our focus presently highlights the hypothesis linking oxidative stress and neurodegeneration to the AD pathogenesis, and indicate that stress responsive genes may represent an important target for novel cytoprotective strategies, as molecules inducing this defense mechanism, via nutritional and/or pharmacological approaches, can exploit the potential for antidegenerative therapeutic interventions .
At the core of adaptive responses at the cell and origin of biological organization is the concept of hormesis . Hormesis is the expression of integrative adaptive responses that are manifest via a biphasic dose response with very specific quantitative response feature (i.e. maximum amplitude and width of the adaptive response) and induced by either a direct stimulatory response or as a modest overcompensation to a disruption of homeostasis . Detailed assessments of pre- and post-conditioning, the adaptive response in radiation, the priming response, as commonly reported in microbial and plant models, and the so-called steeling effect widely reported in the clinical psychology area, all these phenomena act via hormetic mechanisms and comprise a broadly integrated and evolutionarily based adaptive system that has been highly conserved . Such hormetic dose responses provide a quantitative description of the bounds of biological plasticity , and a measure of the extent to which adaptive processes may be upregulated, which is especially relevant to the comprehension of protective effects induced by plant and fungal species. The hormetic concept is particularly important since it provides reliable estimates of the upper limit for the induction of potential therapeutic responses and should play a key role in the design of experimental studies and clinical trials. Hormesis, expecially in vulnerable biological systems, such as the brain, is of relevant interest to the toxicological community for the dose-response model. Particularly, neurohormesis affects memory, learning and performance, as well as nutritional antioxidants and neurodegenerative responses mediated by oxidative stress in cellular models for various diseases such as AD [9, 17]. In fact, the presence of oxidative stress markers in the brains of patients with neurodegenerative diseases has been recognized which supports the rationale for neuroprotective nutritional interventions based on the action antioxidants and anti-inflammatory agents, such as polyphenols or mushrooms . Neurohormesis can be applied to both polyphenol and nutritional mushroom molecular mechanisms of action. It has been, in fact, known that polyphenols and mushrooms activate the heat shock protein (Hsp) pathway, which plays a crucial role in the cellular stress response. With respect to this, for instance although there is no doubt about the protective effect of HO-1 against oxidative and nitrosative stress, on the contrary, excessive HO-1 upregulation may be toxic for cells. According to this principle, drugs, toxins and natural substances, administered at low doses can result in a positive response, while at higher concentrations promote prevalent toxic effects .
Role of the inflammasome
A direct activation link between inflammation and the pathogenesis of Alzheimer’s disease has been demonstrated by numerous in vitro and in vivo studies. in particular the inflammasome NLRP £ has been identified as a possible therapeutic target for the treatment of neurodegenerative diseases. This hypothesis was accredited by the observation of a deficiency of NLRP3 and caspase-1 in mice AA / PS1 (transgenic mice for chronic deposition of Ab), in which Ab deposits were reduced, resulting in an increase in M2 microglia . We have provided recent evidence of a neuroprotective action of the Hericium erinaceus (MRLs, UK) mushroom when administered orally to rat. In the brain of rats receiving oral administration of Hericium erinaceus, was measured maximum expression of LXA4, an anti-inflammatory compound, in cortex and hippocampus. LXA4 up-regulation was related with an increased amount of proteins, such as thioredoxin, Hsp72 and heme oxygenase-1 involved in cellular stress response .
Plausibly, LXA4 signalling activation and stress-responsive vitagene proteins modulation could serve as a potential therapeutic target for AD-related inflammation and neurodegenerative damage. Our results indicate that nutritional supplementation with an opportune biomass preparation from a well characterized strain of Hericium erinaceus or Coriolus versicolor can induced critical proteins modulation involved in brain age-associated neurodegenerative diseases . In view of the fact that in AD pathology, amyloid plaques accumulation (APs), composed of amyloid-beta peptide (Aβ) aggregates, and neurofibrillary tangles (NFTs) formation, composed of misfolded Tau proteins, are related with a deficit in those mechanisms participating in the induction of cytoprotective proteins (Hsps) or, more generally, cellular pathways of stress tolerance, it is conceivable to hypothesize that in these conditions, administration of Hericium erinaceus or Coriolus versicolor biomass, by enhancing the redox potential and inducing neuroprotection through neurohormetic mechanisms such as vitagenes upregulation, may promote resilience in damaged neurons, and hence resistance to proteotoxic insults and apoptotic neurodegeneration. Consistent with this concept, restoration of normal proteostasis is crucial for neuronal survival. Our research suggests new potential strategies based on the induction of vitagene defence system as a foundamental mechanism to promote proteome homeostasis and hence withstand pathological mechanisms associated to unhealthy aging of the brain associated to neurodegenerative diseases .
Although the polysaccharides derived from mushrooms are hardly synthesizable molecules and the active molecules present in the mushrooms are still not well known, the Asian clinical practice employs preparations derived from mushrooms, including Agaricus campestris, Pleurotus ostreatus and Coriolus versicolor extracts . Polysaccharides obtained from coriolus versicolor (Fig. 2a) are commercially among the best options. This mushroom is known for its medical applications, and is usually used to degrade organic contaminants such as pentachlorophenol (PCP) . Polysaccharide K or Kerstin (PSK) and polysaccharopeptide (PSP) are the main commercial preparations obtained by C versicolor mycelia . These compounds stimulate the production of interleukin-6, interferons, immunoglobulin G, macrophages, and T-lymphocytes by enhancing the immune system against immunosuppressive effects of radiotherapy and chemotherapy. Polysaccharopeptides possess anticancer activity inhibiting the production of superoxide dismutase (SOD) and glutathione peroxidase . Experimental animal and human studies have shown that oral administration of PSK and PSP controlled carcinomas . It is reported that PSK produces apoptosis in HL-60 Human promyelocytic leukaemia cells through the activation of mitochondrial and caspase-dependent pathways  and overexpression of proapoptotic protein Bax . Of particular interest are the polysaccaropeptides produced by Coriolus versicolor, which are used to supplement the chemotherapy and radiotherapy of cancer and infectious diseases. Chronic inflammation favours the progression of Alzheimer’s disease (AD), however identification of mechanisms able of resolving the pro-inflammatory environment stimulating AD pathology remains an area of active investigation [50, 51]. Taking into account this neurobiological rationale, our recent study, carried out to demonstrate a potential neuroprotective role of coriolus versicolor biomass preparation in neuroinflammatory pathogenesis associated with Alzheimer’s disease in rat, has been undertaken to provide experimental evidence that biomass from Coriolus or Hericium regulate important redox sensitive pathways linked to cellular stress response and hence confer neuroprotection [3, 4, 52]. Lipoxin A4 (LXA4) derived from Coriolus is an endogenous eicosanoid capable to resolving inflammation process, acting as an endogenous “braking signal” in the inflammatory cascade. Treatment with the pro-resolving mediator aspirin-triggered lipoxin A4 (ATL), caused cognition improvement, reduced Ab levels, and enhanced phagocytic activity of microglia in Tg2576 transgenic AD mice . Moreover, LXA4 levels declined with age, a finding even more evident in 3xTg-AD mice . LXA4 action is regulated by the interaction with G protein-coupled receptor. N-formyl-peptide receptor 1 (FPRL1), also known as ALX (lipoxin A4 receptor) or CCR12, belongs to the formyl-peptide receptor (FPR)-related family of G protein-coupled receptors (GPCRs) that also includes FPR and FPRL2 [55, 56]. All factors able to increase Lipoxin A4 (LXA4) levels and consequently uptake of Ab by phagocytic cells are a hypothetical therapeutic target for AD. Consistent with this notion, in AD pathology, the accumulation of amyloid plaques (APs), constituted of amyloid-beta peptide (Ab) aggregates, and neurofibrillary tangles (NFTs), constituted of misfolded Tau proteins, is related to a deficiency in the activation of cytoprotective proteins (Hsps) or, more generally, of cellular stress tolerance pathways . In these conditions, it is demonstrated that the administration of Coriolus in the brain of rats causes the maximum induction of LXA4 in cortex and hippocampus. Notably, no significant modifications in I-Kappa-B-Alpha (IkBa), Nuclear Factor Kappa B (NFkB) and cyclooxygenase-2 (COX-2) brain levels were associated with Hsps induction . Furthermore, LXA4 up-regulation is related with Nrf-2 regulated vitagenes, thus increasing the content of proteins involved in cellular oxidative stress response, such as thioredoxin, Hsp72 and heme oxygenase .Therefore the induction of vitagenes, could help vulnerable neurons resist proteotoxic insults and to reduce apoptotic neurodegeneration.
Hericium erinaceus (Fig. 2b) fruit bodies and mycelia contain an extraordinarily large quantity of structurally different bioactive and potentially bioactive components. The reported health-promoting properties of these compounds include anticarcinogenic, antibiotic, antidiabetic, antifatigue, antihypertensive, antihyperlipodemic, antisenescence, cardioprotective, nephroprotective, hepatoprotective, and neuroprotective properties and improvement of anxiety, depression and cognitive function . The antioxidant activity of Hericium erinaceus has been observed in diabetic rat model in which the intra peritoneal (i.p.) administration of an aqueous extract of Hericium erinaceus (100 and 200 mg/kg body weight) resulted in a significant decrease in the serum glucose level, significant increase in the insulin level and attenuated serum lipid profiles (disorders) as compared to control rats. These findings were accompanied by increased activities in the antioxidative enzymes catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) and increased GSH (glutathione) and reduced malondialdehyde (MDA) levels in the liver, suggesting that the mechanism of the health-promoting effects seems to be the result of inhibition of ROS . Endowed with different biological activities, Hericium-derived hericenones and erinacines, isolated from its fruiting body, stimulate nerve growth factor (NGF) synthesis in cultured astrocytes . NGF influences basal forebrain cholinergic neurons modulating the activity of two enzymes, such as cholineacetyltransferase and acetyl cholinesterase. The first pathological events of Alzheimer’s disease are the loss and dysfunction of cholinergic neurons. Hericium erinaceus administration improves cognitive dysfunction. Less, however, is known about the clinical relevance of Hericium erinaceus in regulating neurogenesis in the nervous system and its role in neurodegenerative disorders such as Alzheimer’s disease and other types of dementia. Recently, basic and clinical studies have shown that Alzheimer’s disease is closely associated with amyloid beta (Aβ)-induced neuroinflammation, responsible for, the resident macrophages of the brain, and activated microglia may then promote neuronal injury through the release of proinflammatory and cytotoxic factors, exacerbating the course of the disease . A new neuroprotective strategy, like an oral administration of a biomass Hericium biomass preparation given for 3 month, as done in our recent study  can represent a therapeutic target to minimize the deleterious effects related to oxidative burden, such as that occurring in brain aging and in neurodegenerative disorders. Treatment with Hericium erinaceus caused a significant increase of LXA4 production in most of the brain regions like cortex, hippocampus followed by substantia Nigra, striatum and cerebellum and in a modulated expression of cytoprotective proteins, such as Heme oxygenase 1 (HO-1), Heat Shock Protein 70 (Hsp70) and thioredoxin (TRX). These results are coherent with recent evidence obtained in mice, showing neuroprotection by Hericium erinaceus on Aβ 25–35 peptide-induced cognitive dysfunction [61, 62].
Accumulating evidence has indicated that oxidative stress and excess reactive oxygen and nitrogen intermediates play an important role in the progression of many chronic inflammatory diseases, including cardiovascular diseases, diabetes, and neurodegenerative disorders . Imbalance between ROS generation and antioxidant enzyme activities will cause lipid peroxidation, nuclear and mitochondrial DNA damage and protein oxidation, resulting in brain damage and amnesia . A growing number of studies have demonstrated that dietary interventions regulate mitochondrial ROS production, detoxification and oxidative damage repair. Many (but not all) of these nutritional interventions are related with extension of lifespan, or protection against diseases related with age, in mammals. Emerging nutraceuticals are today showing promise as modulators of mitochondrial redox metabolism capable of eliciting beneficial outcomes. Mushrooms, known for their strong antioxidant properties, have attracted interest due to their potential in neuroprotection, antioxidant, and anti-inflammatory effects, as well as in proteome and mitochondrial homeostasis restoration as a basic mechanism to withstand mitochondrial dysfunction-associated neuroinflammatory disorders.
Research activities in the area of dose response have been funded by the United States Air Force and ExxonMobil Foundation over a number of years. However, such funding support has not been used for the present manuscript (EJC).
Availability of data and materials
‘Not applicable’ in this section.
“All authors had full access to the study and take responsibility for the integrity and the accuracy of the study concept and design. Drafting of the manuscript: ATS, MP, RDP, MS, RC, MTC, MLO, MT, MU, LM, EJC, SC, VC. ATS and MP equally contributed as first author. Critical revision of the manuscript for important intellectual content: VC, SC and EJC. Study supervision: VC and EJC.” All authors read and approved the final manuscript.
Ethics approval and consent to participate
“Not applicable” in this section.
Consent for publication
Not applicable (the manuscript contains no individual person’s data).
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 13.Carelli V, La Morgia C, Valentino ML, Barboni P, Ross-Cisneros FN, Sadun AA. Retinal ganglion cell neurodegeneration in mitochondrial inherited disorders. Biochim Biophys Acta. 2009:518–28.Google Scholar
- 14.Trovato Salinaro A, Cornelius C, Koverech G, Koverech A, Scuto M, Lodato F, Fronte V, Muccilli V, Reibaldi M, Longo A, Uva MG, Calabrese V. Cellular stress response, redox status, and vitagenes in glaucoma: a systemic oxidant disorder linked to Alzheimer’s disease. Front Pharmacol. 2014;5:129. https://doi.org/10.3389/fphar.2014.00129.
- 23.Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L. Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxidative Med Cell Longev. 2017;23:45–55.Google Scholar
- 24.Patel S, Goyal A. Recent developments in mushrooms as anti-cancer therapeutics: a review. 3. Biotech. 2012;2:1–15.Google Scholar
- 26.Hroudova J, Singh N, Fisar Z. Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer’s disease. Biomed Res Int. 2014;56:89–99.Google Scholar
- 31.Bosch ME, Kielian T. Neuroinflammatory paradigms in lysosomal storage diseases. Front Neurosci-Switz. 2015;9:33–46.Google Scholar
- 35.Wang D, Calabrese EJ, Lian B, Lin Z, Calabrese V. Hormesis as a mechanistic approach to understanding herbal treatments in traditional Chinese medicine. Pharmacol Ther. 2017. https://doi.org/10.1016/j.pharmthera.2017.10.013. Nov 8. pii: S0163–7258(17)30263–2.
- 37.Paterson RR, Lima N. Biomedical effects of mushrooms with emphasis on pure compounds. Biom J. 2014;37:357–68.Google Scholar
- 39.Wasser SP. Medicinal mushroom science: current perspectives, advances, evidences, and challenges. Biom J. 2014;37:345–56.Google Scholar
- 42.Wang J, Liu YM, Cao W, Yao KW, Liu ZQ, Guo JY. Anti-inflammation and antioxidant effect of Cordymin, a peptide purified from the medicinal mushroom Cordyceps sinensis, in middle cerebral artery occlusion-induced focal cerebral ischemia in rats. Metab Brain Dis. 2012;27:159–65.CrossRefPubMedGoogle Scholar
- 45.Trovato SA, Pennisi M, Crupi R, Di Paola R, Alario A, Modafferi S, Di Rosa G, Fernandes T, Signorile A, Maiolino L, Cuzzocrea S, Calabrese V. Neuroinflammation and mitochondrial dysfunction in the pathogenesis of Alzheimer’s disease: modulation by Coriolus Versicolor (Yun-Zhi) nutritional mushroom. J Neurol Neuromed. 2017;2:19–28.CrossRefGoogle Scholar
- 50.Figueiredo-Pereira ME, Rockwell P, Schmidt-Glenewinkel T, Serrano P. Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration. Front Mol Neurosci. 2015;7Google Scholar
- 51.Joshi YB, Pratico D. The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype. Front Cell Neurosci. 2015;8:436. https://doi.org/10.3389/fncel.2014.00436.
- 52.Trovato Salinaro A, Siracusa R, Di Paola R, Scuto M, Fronte V, Koverech G, Luca M, Serra A, Toscano MA, Petralia A, Cuzzocrea S, Calabrese V. Redox modulation of cellular stress response and lipoxin A4 expression by Coriolus versicolor in rat brain: relevance to Alzheimer’s disease pathogenesis. Neurotoxicology. 2016;53:350–8.CrossRefGoogle Scholar
- 58.Liang B, Guo ZD, Xie F, Zhao AN. Antihyperglycemic and antihyperlipidemic activities of aqueous extract of Hericium ein experimental diabetic rats. BMC Complement Altern Med. 2013;13:253. https://doi.org/10.1186/1472-6882-13-253.
- 62.McGeer PL, McGeer EG. Innate immunity, local inflammation, and degenerative disease. Sci Aging Knowl Environ. 2002;3:23–32.Google Scholar
- 64.Biasibetti R, Tramontina AC, Costa AP, Dutra MF, Quincozes-Santos A, Nardin P, et al. Green tea (−)epigallocatechin-3-gallate reverses oxidative stress and reduces acetylcholinesterase activity in a streptozotocin-induced model of dementia. Behav Brain Res. 2013;236:186–93.CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.